Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Encellin logo — company profile

Encellin

Founded 2016 United States Mountain View, United States 8 employees Series A Total: $15.80M Biotechnology, Health Care +1

General Information

Company Name Encellin
Founded Year 2016
Location United States Mountain View, United States
Employees 8
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Encellin. To contact Encellin, visit encellin.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Encellin compare?

A PDF of Encellin and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Encellin soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Encellin

Encellin, founded in 2016, is a biotechnology and healthcare startup headquartered in the United States. The company's focus is on advancing next generation therapies, specifically targeting endocrine disorders. Encellin's innovative approach involves developing a minimally invasive implant that delivers therapeutics precisely where needed. This technology combines functional cell therapies with a novel cell encapsulation technology to treat chronic diseases. The company recently secured a significant $9.90M Series A investment on December 13, 2023, with participation from notable investors including Y Combinator and Khosla Ventures. This injection of capital is poised to propel Encellin's research and development efforts, as well as support its mission to revolutionize treatment options for chronic diseases. With a strong foundation and strategic backing, Encellin is well-positioned to make a meaningful impact in the biotechnology and healthcare industries.

Business keywords: Cell Therapy, Implantable Devices, Endocrine Disorders, Therapeutics, Cell Encapsulation, Chronic Diseases, Type 1 Diabetes, Minimally Invasive, Medical Technology, San Francisco, Biotech Innovation, Cell-Based Therapies

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $9.90M 2
Y Combinator Khosla Ventures
Y Combinator, Khosla Ventures
13 Dec 2023
Seed Round $5.90M 4
Y Combinator Khosla Ventures SV LatAm Capital
Y Combinator, Khosla Ventures +2
05 Aug 2021
Seed Round Undisclosed 4
Y Combinator Khosla Ventures SandHill Angels
Y Combinator, Khosla Ventures +2
22 Aug 2019
Grant Undisclosed -
01 May 2017

Encellin Alternatives & Competitors

View All Alternatives
Encellin vs
Revatis
Revatis Belgium

An innovative patented and minimally invasive approach for obtaining stem cells

14 employees
Biotechnology, Health Care
Encellin vs
Caribou Biosciences
Caribou Biosciences United States

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating hu...

IPO
128 employees
Biotechnology, Health Care
Encellin vs
Elixirgen Therapeutics, Inc.
Elixirgen Therapeutics, Inc. United States

Reimagine the Power of RNA

Venture round
13 employees
Biotechnology, Health Care
View all alternatives

FAQ About Encellin

Encellin is focused on advancing next generation therapies, starting with endocrine disorders. We are developing a minimally invasive implant delivering therapeutics where needed. Our technology and patient-driven approach combines functional cell therapies with a novel cell encapsulation technolog...
Encellin was founded in 2016.
Encellin is headquartered in Mountain View, United States.
Encellin operates in Biotechnology, Health Care and Medical Devices. Its work centres on Cell Therapy, Implantable Devices, Endocrine Disorders and Therapeutics.
Encellin has approximately 8 employees.
Encellin has completed 4 funding rounds, raising a total of $15.80M. The latest funding stage is Series A.
Top alternatives and competitors to Encellin include Revatis, Caribou Biosciences, Elixirgen Therapeutics, Inc., Histide, Vensica Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Encellin and Revatis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Encellin, https://bouncewatch.com/company/encellin, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes